GLP-1 and Cardiovascular Health: The SELECT Trial and Beyond
The SELECT trial showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in non-diabetic patients with obesity and prior cardiovascular disease. Cardiovascular benefit appears partly independent of weight loss. Many cardiologists now prescribe GLP-1 for high-risk patients regardless of diabetes status.
The SELECT trial, published in 2023, was a turning point. It showed that semaglutide didn't just help patients lose weight — it reduced major cardiovascular events in non-diabetic patients with obesity and prior cardiovascular disease. This shifted GLP-1 prescribing from weight management toward cardiovascular medicine.
What SELECT showed
The Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) trial:
- 17,604 patients, age 45+, with BMI ≥27 and prior cardiovascular disease, no diabetes
- Randomized to semaglutide 2.4 mg/week or placebo
- Followed ~3 years
Primary endpoint (major adverse cardiovascular events — heart attack, stroke, or cardiovascular death):
- Semaglutide: 6.5%
- Placebo: 8.0%
- 20% relative risk reduction (highly statistically significant)
The benefit appeared independent of weight loss — patients who lost less weight also had cardiovascular benefit, suggesting GLP-1 has direct cardiovascular effects beyond just weight reduction.
What this changed in clinical practice
Before SELECT, GLP-1 was framed as a weight loss / diabetes drug. After SELECT:
- Many cardiologists now consider GLP-1 for high-risk obese patients regardless of diabetes
- Medicare expanded Wegovy coverage specifically for cardiovascular event reduction in patients with established CVD (a 2024 expansion)
- Some treatment guidelines now place GLP-1 alongside statins as evidence-based cardiovascular medications for the right patient
- The "weight loss" framing has shifted toward "metabolic and cardiovascular intervention"
How GLP-1 helps the heart
Multiple mechanisms:
1. Weight loss. Reduces blood pressure, improves lipids, reduces visceral fat — all cardiovascular benefits.
2. Blood sugar improvement. Better glycemic control reduces atherosclerosis progression.
3. Anti-inflammatory effects. GLP-1 has direct anti-inflammatory effects on blood vessels.
4. Reduced visceral fat specifically. Visceral fat is the most cardiometabolically dangerous; GLP-1 preferentially reduces it.
5. Direct cardiovascular receptor effects. GLP-1 receptors are in the heart and blood vessels themselves.
6. Improved lipid profile. Reduced triglycerides, modest LDL reduction, often improved HDL.
7. Blood pressure reduction. Average ~5 mmHg reduction in systolic BP.
Other cardiovascular trials
SELECT is the headline, but the cardiovascular GLP-1 evidence base is broad:
- LEADER (liraglutide in diabetics): 13% reduction in major CV events
- SUSTAIN-6 (semaglutide in diabetics): 26% reduction in major CV events
- REWIND (dulaglutide in diabetics): 12% reduction in major CV events
- HARMONY (albiglutide): 22% reduction
- PIONEER 6 (oral semaglutide): trend toward CV benefit, not significant
- SURPASS-CVOT (tirzepatide): ongoing — results expected to show cardiovascular benefit
The pattern is consistent: GLP-1 medications generally produce ~10–25% reductions in cardiovascular events.
Who benefits most
The cardiovascular benefit appears strongest in patients with:
- Established cardiovascular disease (prior heart attack, stroke, peripheral arterial disease)
- Multiple risk factors (diabetes + hypertension + obesity)
- High-risk lipid profiles
- Chronic kidney disease (which is itself a CV risk amplifier)
Patients without established CV disease and without significant risk factors derive less absolute benefit, though the relative benefit is similar.
Combining with other CV medications
GLP-1 is generally safely combined with:
- Statins
- Blood pressure medications
- Aspirin
- Other diabetes medications (with insulin/sulfonylurea dose adjustments)
The combinations often produce additive benefit. A patient on a statin, ACE inhibitor, and GLP-1 has substantially better cardiovascular outcomes than any one alone.
What about heart failure?
GLP-1 effects in heart failure are still being characterized:
- STEP-HFpEF (semaglutide in heart failure with preserved ejection fraction): Significant symptom and biomarker improvements
- Reduced concerns about earlier heart failure signals (no longer considered a risk in current data)
- Generally considered safe in stable heart failure
- Acute heart failure: caution; not first-line
Talk to your cardiologist if you have any heart failure history.
The kidney connection
Kidney function intersects significantly:
- FLOW trial (semaglutide in CKD with diabetes): Reduced kidney disease progression
- GLP-1 generally protective for kidney function in obese / diabetic patients
- Acute kidney injury risk in patients with severe nausea/vomiting and dehydration — staying hydrated matters
What this means for patients
If you have cardiovascular disease + obesity (with or without diabetes), GLP-1 is increasingly considered a standard-of-care option. Discuss with your cardiologist or PCP.
If you're considering GLP-1 primarily for cardiovascular reasons, useful framing for the conversation:
- "I have obesity + prior CV event — does the SELECT data apply to me?"
- "Could Wegovy be part of my cardiovascular prevention plan?"
- "Would my insurance cover it under the cardiovascular indication now?"
Bottom line
GLP-1 medications reduce major cardiovascular events by ~10–25% across multiple large trials. SELECT specifically showed 20% reduction in non-diabetic obese patients with prior CV disease. The benefit appears partly independent of weight loss. Patients with established cardiovascular disease + obesity should discuss GLP-1 with their cardiologist; the framing has shifted from "weight loss drug" to "evidence-based cardiovascular medication for the right patient."